Subcutaneous ketamine infusion in palliative patients for major depressive disorder (SKIPMDD)-Phase II single-arm open-label feasibility study.

<h4>Background</h4>Ketamine at subanaesthetic dosages (≤0.5mg/kg) exhibits rapid onset (over hours to days) antidepressant effects against major depressive disorder in people who are otherwise well. However, its safety, tolerability and efficacy are not known for major depressive disorder in people...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Wei Lee, Caitlin Sheehan, Richard Chye, Sungwon Chang, Adam Bayes, Colleen Loo, Brian Draper, Meera R Agar, David C Currow
Format:	Artigo
Sprog:	Inglês
Udgivet:	Public Library of Science (PLoS) 2023-01-01
Serier:	PLoS ONE
Online adgang:	https://doi.org/10.1371/journal.pone.0290876
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!